One in five Australian children start school with a speech or language disorder.

Some children will grow out of it, but others will go on to have persistent communication difficulties.

 

We know that speech and language disorders arise from genetic, neurological and environmental factors. Genetic factors are thought to play a significant role to speech and language.

 

We have identified that as many as 1 in 3 children with speech apraxia may receive a genetic diagnosis for their condition.

 

The team have also identified over 30 single genes causative for a rare but persistent speech disorder, known as childhood apraxia of speech.

Our Latest News

NEW STUDY: speech and language in individuals with SYNGAP1-DEE

NEW STUDY: speech and language in individuals with SYNGAP1-DEE

Our Speech & Language team is launching an international research study examining speech and language outcomes in individuals with SYNGAP1-developmental and epileptic encephalopathy. 

Hear Ms Alecka Garrett, PhD candidate and speech pathologist, discuss the study in this informative reel.
Childhood Apraxia of Speech Trial

Childhood Apraxia of Speech Trial
We are trialling a new treatment for children with childhood apraxia of speech (CAS). This treatment is the drug methylphenidate (MPH), commonly known as Ritalin. We want to find out whether MPH can help improve the speech and language symptoms of CAS in children aged 6-12 years.
Hear Ms Lorraine O'Donnell, Registered Nurse and Coordinator of this trial, explain our study in this informative reel.

Proudly in partnership with